Arunjyoti Bio Ventures Limited Reports Share Acquisition by Chennupati Sarath Kumar

1 min read     Updated on 17 Apr 2026, 10:39 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Arunjyoti Bio Ventures Limited reported a share acquisition by Chennupati Sarath Kumar under SEBI disclosure requirements. The non-promoter acquired 54,25,516 equity shares representing 2.91% of the company's total capital through open market transactions between April 13-16, 2026, changing his shareholding position in the BSE-listed company.

powered bylight_fuzz_icon
37453793

*this image is generated using AI for illustrative purposes only.

Arunjyoti bio ventures Limited has filed a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reporting a share acquisition transaction by Chennupati Sarath Kumar. The disclosure, dated April 16, 2026, was submitted to BSE Limited where the company's shares are listed.

Transaction Details

Chennupati Sarath Kumar, who is not part of the promoter or promoter group, acquired shares in the company through open market transactions. The acquisition was executed over a period spanning from April 13, 2026, to April 16, 2026.

Transaction Parameter: Details
Shares Acquired: 54,25,516 equity shares
Percentage of Total Capital: 2.91%
Transaction Mode: Open Market
Transaction Period: April 13, 2026 to April 16, 2026
Acquirer Category: Non-Promoter

Shareholding Pattern Changes

The transaction resulted in an increase in Chennupati Sarath Kumar's stake in Arunjyoti Bio Ventures Limited. His shareholding position changed following the completion of the acquisition.

Shareholding Details: Before Acquisition After Acquisition Change
Number of Shares: 1,41,01,138 86,75,622 +54,25,516
Percentage Holding: 7.57% 4.66% +2.91%

Company Capital Structure

The company's equity share capital structure remained unchanged following this transaction. Arunjyoti Bio Ventures Limited maintains its existing capital base without any alterations to the total number of shares or their face value.

Capital Structure: Details
Total Equity Capital: Rs. 18,63,81,000
Number of Shares: 18,63,81,000
Face Value per Share: Re. 1/-
Listing Exchange: BSE Limited
Scrip Code: 530881

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations governing substantial acquisition and disposal of shares. The transaction falls under the purview of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates disclosure when shareholding changes exceed specified thresholds. The filing ensures transparency and keeps investors informed about significant changes in shareholding patterns of listed companies.

Historical Stock Returns for Arunjyothi Bio Ventures

1 Day5 Days1 Month6 Months1 Year5 Years
+4.97%-14.27%0.0%-46.22%-25.74%+2,747.83%

What strategic plans might Chennupati Sarath Kumar have for his increased 7.57% stake in Arunjyoti Bio Ventures?

Could this significant acquisition signal potential consolidation or partnership opportunities in the biotechnology sector?

How might this shareholding change impact Arunjyoti Bio Ventures' board composition and corporate governance decisions?

Arunjyothi Bio Ventures
View Company Insights
View All News
like15
dislike

Arunjyoti Bio Ventures Limited Issues Warning Against Unsolicited Messages Circulating About Company Scrip

1 min read     Updated on 14 Apr 2026, 01:49 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Arunjyoti Bio Ventures Limited has issued a regulatory disclosure to BSE Limited on April 13, 2026, under SEBI (LODR) Regulations, warning about unsolicited messages circulating regarding the company's scrip. The company has advised investors to exercise caution while trading shares, with the disclosure signed by Whole-Time Director Pabbathi Badari Narayana Murthy (DIN: 01445523).

powered bylight_fuzz_icon
37657193

*this image is generated using AI for illustrative purposes only.

Arunjyoti Bio Ventures Limited has issued an important regulatory disclosure to BSE Limited regarding unsolicited messages being circulated about the company's scrip. The formal communication, dated April 13, 2026, was made under Regulation 30(11) of SEBI (LODR) Regulations, 2015.

Regulatory Disclosure Details

The company has been informed about instances of unsolicited messages being circulated in relation to Arunjyoti Bio Ventures Limited's scrip. This disclosure represents the company's proactive approach to maintaining transparency and protecting investor interests in compliance with securities regulations.

Parameter: Details
Disclosure Date: April 13, 2026
Regulation: SEBI (LODR) Regulations, 2015 - Section 30(11)
Exchange: BSE Limited
Subject Matter: Unsolicited messages in company scrip

Investor Advisory

In response to these developments, Arunjyoti Bio Ventures Limited has issued a clear advisory to investors. The company has specifically advised investors to take due care and caution while dealing in shares of the company. This precautionary measure aims to protect shareholders from potential misinformation or manipulative activities that may affect trading decisions.

Management Authorization

The disclosure was formally authorized and signed by Pabbathi Badari Narayana Murthy, who serves as the Whole-Time Director of the company. His Director Identification Number (DIN) is 01445523, and the document bears his digital signature along with the official company stamp.

Regulatory Compliance

This disclosure demonstrates the company's commitment to maintaining regulatory compliance and transparency standards as mandated by SEBI regulations. The timely communication to BSE Limited reflects the company's adherence to disclosure norms designed to protect investor interests and maintain market integrity.

Historical Stock Returns for Arunjyothi Bio Ventures

1 Day5 Days1 Month6 Months1 Year5 Years
+4.97%-14.27%0.0%-46.22%-25.74%+2,747.83%

Will SEBI launch an investigation into the source and nature of these unsolicited messages targeting Arunjyoti Bio Ventures?

How might this incident affect investor confidence and trading volumes in Arunjyoti Bio Ventures' stock in the coming weeks?

What specific measures will the company implement to prevent future circulation of misleading information about its scrip?

Arunjyothi Bio Ventures
View Company Insights
View All News
like15
dislike

More News on Arunjyothi Bio Ventures

1 Year Returns:-25.74%